Comparison of fluoroquinolone kinetics of kill in susceptible and resistant Gram-Positive conjunctival pathogens

Advances in Therapy

Volumn 27, Issue 1, 2010, Pages 39-47

  D'Arienzo, Peter A ^a   Wagner, Rudolph S ^b   Jamison, Tiffany ^c   Bell, Belinda ^c   Dajcs, Joseph J ^c   Stroman, David W ^c  

^a Catholic Medical Center of Brooklyn and Queens   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c ALCON RESEARCH LTD   (United States)

Author keywords

Bacterial conjunctivitis; In vitro; Rate of kill; Resistant; Staphylococcus aureus; Streptococcus pneumoniae; Susceptible

Indexed keywords

CIPROFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; BACTERIUM ISOLATION; COLONY FORMING UNIT; CONJUNCTIVA; NONHUMAN; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BACTERIOLOGICAL TECHNIQUES; CIPROFLOXACIN; CONJUNCTIVITIS, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUOROQUINOLONES; HUMANS; OFLOXACIN; QUINOLINES; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TIME FACTORS;

EID: 77950689826     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-010-0004-y     Document Type: Article

References (10)

1. Gigliotti F, Williams WT, Hayden FG, et al. Etiology of acute conjunctivitis in children. J Pediatr. 1981;98:531-536.
2. Weiss A, Brinser JH, Nazar-Stewart V. Acute conjunctivitis in childhood. J Pediatr. 1993;122:10-14.
3. Patel PB, Diaz MC, Bennett JE, Attia MW. Clinical features of bacterial conjunctivitis in children. Acad Emerg Med. 2007;14:1-5.
4. Stroman DW, Cupp GA, Schlech BA. Resistance patterns in conjunctivitis and blepharitis in 2006.Invest Ophthalmol Vis Sci. 2007;48:2680.
5. Soukiasian SH, Baum J. Bacterial conjunctivitis. In: Krachmer JH, Mannis MJ, Holland EJ, eds. Cornea. Version 2. St. Louis, MI: Elsevier-Mosby; 2005:759-3172.
6. Lichtenstein SJ, Wagner RS, Jamison T, Bell B, Stroman DW. Speed of bacterial kill with a fluoroquinolone compared with nonfluoroquinolones: clinical implications and a review of kinetics of kill studies. Adv Ther. 2007;24:1098-1111.
7. Wagner RS, Granet DB, Lichetenstein SL, et al. Kinetics of kill of bacterial conjunctivitis isolates with moxifloxacin, a fluoroquinolone, compared with the aminoglycosides tobramycin and gentamicin. Clin Ophthalmol. 2010;4:41-45.
8. Stroman DW, Dajcs JJ, Cupp GA, Schlech BA. In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone. Surv Ophthalmol. 2005;50(suppl. 1):S16-S31.
9. Wagner RS, Abelson MB, Shapiro A, Torkildsen G. Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue. Arch Ophthalmol. 2005;123:1282-1283.
10. Lichtenstein SJ, Dorfman M, Kennedy R, Stroman D. Controlling contagious bacterial conjunctivitis. J Pediatr Ophthalmol Strabismus. 2006;43:19-26.